Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novo Nordisk |
---|---|
Information provided by: | Novo Nordisk |
ClinicalTrials.gov Identifier: | NCT00266006 |
This trial is conducted in Japan. The purpose of this trial is to evaluate the safety and preliminary efficacy of Activated Recombinant Factor VII (NN-007) in patients with acute intracerebral haemorrhage.
Condition | Intervention | Phase |
---|---|---|
Intracerebral Haemorrhage |
Drug: activated recombinant human factor VII |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Factorial Assignment, Safety/Efficacy Study |
Official Title: | Safety of Eptacog Alfa (Activated) (Genetical Recombination) on Adverse Events and Serious Adverse Events in Patients With Acute Intracerebral Haemorrhage. |
Ages Eligible for Study: | 20 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Novo Nordisk A/S ( Public Access to Clinical Trials ) |
Study ID Numbers: | F7ICH-1602, JAPIC: JapicCTI-050194 |
Study First Received: | December 14, 2005 |
Last Updated: | November 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00266006 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Cerebral Hemorrhage Vascular Diseases Central Nervous System Diseases Intracranial Hemorrhages |
Brain Diseases Hemorrhage Cerebrovascular Disorders |
Pathologic Processes Nervous System Diseases Cardiovascular Diseases |